NCT01119846 - A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

June 5, 2009

Primary Completion Date

March 19, 2010

Study Completion Date

March 19, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK1292263

GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.

DRUG

GSK1292263 matching placebo

Matching placebo to active drug GSK1292263

DRUG

Sitagliptin

"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."

Trial Locations (7)

27705

GSK Investigational Site, Durham

33169

GSK Investigational Site, Miami

43212

GSK Investigational Site, Columbus

78209

GSK Investigational Site, San Antonio

85013

GSK Investigational Site, Phoenix

91910

GSK Investigational Site, Chula Vista

98418

GSK Investigational Site, Tacoma